# Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

> **NCT01042041** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer
- Localized Unresectable Liver Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** cisplatin
- **DRUG:** mitomycin C
- **PROCEDURE:** transarterial chemoembolization
- **PROCEDURE:** hepatic artery embolization

## Key facts

- **NCT ID:** NCT01042041
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042041, "Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01042041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*